Cargando…

Bronchopulmonale Dysplasie (BPD)

OLD VS. NEW BPD: Bronchopulmonary dysplasia (BPD) was described about 50 years ago as a fibroproliferative chronic lung disease in consequence of mechanical ventilation/oxygen exposure in premature infants with respiratory distress syndrome (old BPD). Surfactant therapy with increased survival of ex...

Descripción completa

Detalles Bibliográficos
Autor principal: Herting, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095785/
https://www.ncbi.nlm.nih.gov/pubmed/32226158
http://dx.doi.org/10.1007/s00112-012-2800-8
_version_ 1783510685484843008
author Herting, E.
author_facet Herting, E.
author_sort Herting, E.
collection PubMed
description OLD VS. NEW BPD: Bronchopulmonary dysplasia (BPD) was described about 50 years ago as a fibroproliferative chronic lung disease in consequence of mechanical ventilation/oxygen exposure in premature infants with respiratory distress syndrome (old BPD). Surfactant therapy with increased survival of extremely premature infants identified a new type of an immaturity-related multisystem disorder that is characterized by a stop/simplification of alveolarisation and lung capillary development (new BPD). THERAPY: To date, mainly symptomatic treatment exists. However, growth factors and stem cell therapy have recently been tested with some success in animal experiments. OUTCOME: Survivors of new BPD may have problems in adult life concerning lung and cardiovascular function, growth and neurosensory and/or motor development.
format Online
Article
Text
id pubmed-7095785
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-70957852020-03-26 Bronchopulmonale Dysplasie (BPD) Herting, E. Monatsschr Kinderheilkd Leitthema OLD VS. NEW BPD: Bronchopulmonary dysplasia (BPD) was described about 50 years ago as a fibroproliferative chronic lung disease in consequence of mechanical ventilation/oxygen exposure in premature infants with respiratory distress syndrome (old BPD). Surfactant therapy with increased survival of extremely premature infants identified a new type of an immaturity-related multisystem disorder that is characterized by a stop/simplification of alveolarisation and lung capillary development (new BPD). THERAPY: To date, mainly symptomatic treatment exists. However, growth factors and stem cell therapy have recently been tested with some success in animal experiments. OUTCOME: Survivors of new BPD may have problems in adult life concerning lung and cardiovascular function, growth and neurosensory and/or motor development. Springer-Verlag 2013-04-28 2013 /pmc/articles/PMC7095785/ /pubmed/32226158 http://dx.doi.org/10.1007/s00112-012-2800-8 Text en © Springer-Verlag Berlin Heidelberg 2013 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Herting, E.
Bronchopulmonale Dysplasie (BPD)
title Bronchopulmonale Dysplasie (BPD)
title_full Bronchopulmonale Dysplasie (BPD)
title_fullStr Bronchopulmonale Dysplasie (BPD)
title_full_unstemmed Bronchopulmonale Dysplasie (BPD)
title_short Bronchopulmonale Dysplasie (BPD)
title_sort bronchopulmonale dysplasie (bpd)
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095785/
https://www.ncbi.nlm.nih.gov/pubmed/32226158
http://dx.doi.org/10.1007/s00112-012-2800-8
work_keys_str_mv AT hertinge bronchopulmonaledysplasiebpd